Cronos CRON stock analysis and how Cronos CRON stock gets to profitability

Pres­i­dent Don­ald Trump’s com­mu­ni­ca­tions pause for HHS, FDA and oth­er health-re­lat­ed agen­cies could push some drug ap­proval de­ci­sions to lat­er dates, a Ray­mond James an­a­lyst

The FDA extended indications for alectinib (Alecensa) to include adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first such approval for an ALK